Type I and type II reactions in TRAIL-induced apoptosis -- results from dose-response studies. - Wikidata - awgldk - TriplyDB

Type I and type II reactions in TRAIL-induced apoptosis -- results from dose-response studies.

Type I and type II reactions in TRAIL-induced apoptosis -- results from dose-response studies.

http://www.wikidata.org/entity/Q33208795

about

Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis Onto better TRAILs for cancer treatment Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway.Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma.Protein kinase Cepsilon inhibits UVR-induced expression of FADD, an adaptor protein, linked to both Fas- and TNFR1-mediated apoptosis.BITC Sensitizes Pancreatic Adenocarcinomas to TRAIL-induced Apoptosis Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer Lyapunov exponents and phase diagrams reveal multi-factorial control over TRAIL-induced apoptosis.c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis.Cordycepin induced MA-10 mouse Leydig tumor cell apoptosis by regulating p38 MAPKs and PI3K/AKT signaling pathways Protein kinase Cepsilon makes the life and death decision.Molecular targeted approaches for treatment of pancreatic cancer.Targeting TRPM2 Channels Impairs Radiation-Induced Cell Cycle Arrest and Fosters Cell Death of T Cell Leukemia Cells in a Bcl-2-Dependent Manner TRAIL receptor-targeted therapy.TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.Monoclonal antibodies in the treatment of pancreatic cancer.Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype.Interactions of acetylcholinesterase with caveolin-1 and subsequently with cytochrome c are required for apoptosome formation.Downregulation of Bid is associated with PKCepsilon-mediated TRAIL resistance.Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4.Loss of caspase-9 provides genetic evidence for the type I/II concept of CD95-mediated apoptosis.Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay.Differential growth inhibition and induction of apoptosis by gossypol between HCT116 and HCT116/Bax(-/-) colorectal cancer cells.Pro-apoptotic effect of TRAIL-transfected endothelial progenitor cells on glioma cells.N-glycosylation of mouse TRAIL-R restrains TRAIL-induced apoptosis.

P2860

Q21260429-475D822B-DB9E-468A-8131-AB7EC54E9F50 Q24535730-320BD178-73F9-48A4-9373-DC2EB010D3C7 Q24798681-349B00A5-AFB8-40FD-9A8C-DA88DD181BD5 Q26768160-93AB21A8-CCB5-4A8F-BA9A-E36FA7427E3B Q33218586-A19716D3-51EF-4312-A616-4C7A2A2ECED2 Q33544118-BFB002BB-F27F-4301-A354-F0D32667B8B8 Q33786961-D75EF251-DD40-4C45-8B6C-39A2D5C4A5AE Q33915871-62A18600-92FB-49A5-8D2C-0CC49D71261E Q34610496-02071729-5CEC-45A0-A1EF-34673695B6CB Q35682077-188B4E90-8C8F-4433-8DFB-291A1AACC592 Q35752871-F524817C-684A-4233-8C30-88FCA184D2FB Q35992659-72D5B056-39A8-4CE9-B769-70366EA39FB3 Q36002759-8AA9B712-7381-4548-8ADD-E4BFF16C0D91 Q36174910-C8E4DE5D-8E1E-4CEA-BFB0-B15B49414332 Q36453864-618FB515-6493-4C03-B8E4-739CE96017DA Q36572530-93F1764F-0DB1-4425-951B-EB29D9581C50 Q36731174-A79DD10C-A92B-4978-B727-580396D76EE7 Q37355568-6C58A2A8-0FB5-41ED-BEC5-677206D4BC4E Q37610475-9F65B807-0620-417E-ADAC-BC4B8A8DB9A1 Q39977133-28295C04-2C28-4CF1-9209-88B9018981B6 Q40015399-00C601F2-B986-47D2-A3B6-32EE535E8761 Q40191065-DDBB1575-63DE-4C99-AD3F-B92AC3FC03DA Q40198109-872A6728-9EB9-4628-A2C4-3797EC44EC9D Q40245914-6790D4BC-9987-4731-91B0-68D402EDABDA Q40254359-D2CD1AB0-34A8-49E3-99DE-4082F1AD79C5 Q44926501-9CBC485C-9A33-4AEB-BA0E-1D4B7516FA5D Q52653034-3C4AAC78-BA63-452F-86C5-74C749FBA970 Q55156410-A9C1A807-A76E-49F2-AE70-4B55C8B72C05

P2860

Type I and type II reactions in TRAIL-induced apoptosis -- results from dose-response studies.

http://www.wikidata.org/entity/Q33208795

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Type I and type II reactions i ...... ts from dose-response studies.

@ast

Type I and type II reactions i ...... ts from dose-response studies.

@en

type

label

Type I and type II reactions i ...... ts from dose-response studies.

@ast

Type I and type II reactions i ...... ts from dose-response studies.

@en

prefLabel

Type I and type II reactions i ...... ts from dose-response studies.

@ast

Type I and type II reactions i ...... ts from dose-response studies.

@en

P1433

Q33208795-53CED08E-219A-45B0-A36F-4FF6F299668E

P1476

Q33208795-39EDF648-07A2-4206-86F8-02A4A0A8D693

P2093

Q33208795-13B3D143-9A18-4DFE-BF04-458D7A63F878

Q33208795-19100040-5C27-447B-A8C5-5D39EC0F1640

Q33208795-56C6ED99-5C6E-4E10-8C1B-B75E4375E92F

Q33208795-A77E31D0-DD01-48B6-8907-C4D192FDBA6B

Q33208795-D4B07740-65FB-48DD-BCBF-880C58108F68

P2860

Q33208795-0E02411B-A183-407A-B6D5-7D5CA69FE31E

Q33208795-11750EBE-BA79-417B-8885-1E13D3F307FC

Q33208795-19678747-4DAD-444C-BEB0-84BAB137C0B8

Q33208795-21D832C0-4430-426D-8BD9-34F30FE5E242

Q33208795-3C725133-3799-4B57-9EAC-EB260D96E8AB

Q33208795-3C8DEB9A-324C-48DF-B4FD-1CA8C2273256

Q33208795-3FD0E513-19AD-438E-83F5-738461DB72B4

Q33208795-40F8AD6C-01DA-4F97-8EEF-15EA5ACD745D

Q33208795-488A58F0-FFB2-4756-A93F-71A54658D8E5

Q33208795-56E5273B-7E8F-4DC0-B683-470E5E70930B

P2888

Q33208795-C2A568C8-291A-4D7F-956A-775457FD69A2

P304

Q33208795-B7A8E2DD-D5AC-46F1-B27B-08B8EE3F8987

P31

Q33208795-91774406-DC2F-4CB4-AF48-3B1F900692AA

P356

Q33208795-7C7385D4-3816-494B-B28C-6D85F336E5FC

P407

Q33208795-2E3D48F0-5307-46C9-BF72-2774F4D6BC03

P433

Q33208795-EEE07421-6890-4C5D-AFA6-558E7482DDA6

P478

Q33208795-82028EB1-D396-4AFB-8EF6-8AC971A88838

P50

Q33208795-526B6E2B-78F3-4F2B-B29F-863DC55A2C1F

P577

Q33208795-90B7D65D-D76C-4EFD-AA18-699ED1117FB3

P5875

Q33208795-AA7A662F-323B-4F06-8FBA-947FF66D5778

P6179

Q33208795-7A871165-A728-4274-9DA0-038FBE95633E

P698

Q33208795-99D19EF4-315A-4BB7-9A2B-D2E3579D2DD0

P356

P1433

P1476

Type I and type II reactions i ...... lts from dose-response studies

@en

P2093

Claus Belka

http://www.w3.org/2001/XMLSchema#string

Justine Rudner

http://www.w3.org/2001/XMLSchema#string

Kirsten Lauber

http://www.w3.org/2001/XMLSchema#string

Peter T Daniel

http://www.w3.org/2001/XMLSchema#string

Verena Jendrossek

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Bid-induced apoptosis by Bcl-2. tBid insertion, Bax translocation, and Bax/Bak oligomerization suppressed

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8

Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation

Disruption of cell death signaling in cancer: impact on disease prognosis and response to therapy.

Safety and antitumor activity of recombinant soluble Apo2 ligand.

An induced proximity model for caspase-8 activation.

Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation

Potential and caveats of TRAIL in cancer therapy.

Anti-apoptotic Bcl-2 proteins: structure, function and relevance for radiation biology.

P2888

P304

130-140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1208191

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Sebastian Wesselborg

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8188772

http://www.w3.org/2001/XMLSchema#string

P6179

1030634267

http://www.w3.org/2001/XMLSchema#string

P698

15531922

http://www.w3.org/2001/XMLSchema#string